[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1318
1. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol; 2007 Mar;82(1):81-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
  • Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / radiotherapy. Radiation-Sensitizing Agents / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Necrosis. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 May 1;97(9):2262-6 [12712481.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Neurology. 2004 Aug 10;63(3):535-7 [15304589.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 16944309.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Radiation-Sensitizing Agents; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


2. Pothiawala S, Hsu MY, Yang C, Kesari S, Ibrahimi OA: Urticarial hypersensitivity reaction caused by temozolomide. J Drugs Dermatol; 2010 Sep;9(9):1142-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers.
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Astrocytoma / complications. Astrocytoma / drug therapy. Brain Neoplasms / complications. Brain Neoplasms / drug therapy. Eosinophils / pathology. Fluocinonide / administration & dosage. Fluocinonide / therapeutic use. Histamine H1 Antagonists / administration & dosage. Histamine H1 Antagonists / therapeutic use. Humans. Male. Skin / pathology

  • MedlinePlus Health Information. consumer health - Hives.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20865848.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Histamine H1 Antagonists; 2W4A77YPAN / Fluocinonide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


3. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther; 2006 Jan;13(1):221-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.
  • We undertook a Phase I/II trial in patients with apparent recurrent glioblastoma multiforme (GBM) based on imaging studies to determine the safety and tumor response of repetitive intravenous administration of NDV-HUJ, the oncolytic HUJ strain of Newcastle disease virus.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / therapy. Glioblastoma / therapy. Newcastle disease virus. Oncolytic Virotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Injections, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local


Advertisement
4. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology; 2008 Mar 4;70(10):779-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six-month progression-free survival (PFS) was 42% for patients with glioblastoma and 32% for patients with anaplastic glioma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / toxicity. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bevacizumab. Brain / drug effects. Brain / pathology. Brain / physiopathology. Clinical Trials as Topic / statistics & numerical data. Disease-Free Survival. Drug Resistance, Neoplasm / physiology. Drug Synergism. Female. Humans. Magnetic Resonance Imaging. Male. Meta-Analysis as Topic. Middle Aged. Retrospective Studies. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2009 Feb 24;72(8):773; author reply 773-4 [19248218.001]
  • [CommentIn] Neurology. 2009 Feb 24;72(8):772-3; author reply 773-4 [19237713.001]
  • (PMID = 18316689.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


5. Burnet NG, Jena R, Jefferies SJ, Stenning SP, Kirkby NF: Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. Clin Oncol (R Coll Radiol); 2006 Mar;18(2):93-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment.
  • AIMS: The outcome of patients with glioblastoma (GBM) remains extremely poor.
  • MATERIALS AND METHODS: Survival data were available for 154 adult patients with GBM treated in our centre with curative intent to a dose of 60 Gy in 30 fractions between 1996 and 2002.
  • The model generates the equivalent of individual patients with a brain tumour, and produces an explicit outcome, either death or survival.
  • The tumour, assumed to be growing exponentially, causes normal cell damage in the brain, and death occurs when the number of normal brain cells falls below a critical level.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Decision Support Techniques. Dose Fractionation. Glioblastoma / pathology. Glioblastoma / radiotherapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Oncol (R Coll Radiol). 2006 Sep;18(7):578-9 [16969995.001]
  • (PMID = 16523808.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861383
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ, EORTC Brain Tumour Group investigators: Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer; 2008 Jun;44(9):1210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In a previous randomised EORTC study on adjuvant dibromodulcitol (DBD) and bichloroethylnitrosourea (BCNU) in adults with glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), a clinically significant trend towards a longer overall survival (OS) and a progression-free survival (PFS) was observed in the subgroup of AA.
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Carmustine / adverse effects. Chemotherapy, Adjuvant. Female. Hematologic Diseases / chemically induced. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mitolactol / administration & dosage. Mitolactol / adverse effects. Treatment Failure

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248979.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA 11488
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] LJ2P1SIK8Y / Mitolactol; U68WG3173Y / Carmustine
  • [Investigator] Afra D; Maat B; Hildebrand J; de Wit O; Frenay F; Chatel M; Rivier I; Taphoorn M; Delattre JY; de Tribolet N; Stupp R; Punt J; Garfield J; Chinot O; van den Bent M; Lahrmann H; Cristo C; Mouchamps M; Haferkamp G; Bravo Marques J
  •  go-up   go-down


7. Kong DS, Nam DH, Lee JI, Park K, Kim JH: Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme. J Neurosurg; 2006 Dec;105 Suppl:139-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme.
  • OBJECT: The authors conducted a retrospective study to evaluate the efficacy of Gamma Knife surgery (GKS) followed by radiotherapy for the treatment of unresectable glioblastomas multiforme (GBMs) on patient survival and quality of life.
  • METHODS: A total of 19 patients with unresectable GBMs located in eloquent areas of the brain were eligible for this study.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Glioblastoma / radiotherapy. Glioblastoma / surgery. Neoadjuvant Therapy. Quality of Life. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18503347.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Konya D, Yildirim O, Kurtkaya O, Kiliç K, Black PM, Pamir MN, Kiliç T: Testing the angiogenic potential of cerebrovascular malformations by use of a rat cornea model: usefulness and novel assessment of changes over time. Neurosurgery; 2005 Jun;56(6):1339-45; discussion 1345-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme tissues, normal adult brain tissues, and normal brain artery tissues were used as controls.
  • RESULTS: Of the three CVM types, the AVMs showed the highest angiogenic activity, cavernous malformations exhibited some degree of angiogenic activity (less than AVMs but more than normal brain artery tissue), and angiogenesis induction by venous angiomas was comparable to that of normal brain artery tissue.
  • [MeSH-minor] Adolescent. Adult. Animals. Disease Models, Animal. Humans. Immunohistochemistry / methods. Middle Aged. Random Allocation. Rats. Retrospective Studies. Time Factors. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918951.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


9. Khatri RG, Navaratne K, Weil RJ: The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. J Neurosurg; 2008 Nov;109(5):842-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
  • OBJECT: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, with a 5-year survival rate of < 5%.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Polymorphism, Single Nucleotide / genetics. Proto-Oncogene Proteins c-mdm2 / genetics
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Base Sequence. Case-Control Studies. Cohort Studies. DNA, Neoplasm / genetics. Female. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Molecular Sequence Data. Prospective Studies. Retrospective Studies. Tumor Suppressor Protein p53 / physiology. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976073.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


10. Paldino MJ, Barboriak D, Desjardins A, Friedman HS, Vredenburgh JJ: Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme. J Magn Reson Imaging; 2009 May;29(5):1199-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.
  • PURPOSE: To quantify the repeatability of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in patients with glioblastoma multiforme.
  • Sixteen patients with glioblastoma multiforme underwent MR imaging at two time points without interval intervention.
  • [MeSH-major] Algorithms. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / diagnosis. Image Interpretation, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388113.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK: Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol; 2008 Oct;90(1):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
  • Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of glioblastoma patients.
  • Patients with recurrent glioblastoma with no more than two prior relapses received carboplatin intravenously on day 1 of every 28-day cycle (target AUC of 6 mg x ml/min).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Erlotinib Hydrochloride. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. PTEN Phosphohydrolase / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Quinazolines / administration & dosage. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2288-94 [17538175.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):609-12 [8931682.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Mutat Res. 1992 May;276(3):299-306 [1374522.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Neurooncol. 1991 Aug;11(1):27-35 [1919643.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):759-61 [14990627.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1 [15376352.001]
  • [Cites] Adv Exp Med Biol. 2003;532:235-46 [12908562.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Brain Tumor Pathol. 1998;15(1):53-7 [9879464.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1369-72 [16177570.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602-6 [2236070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Nov;291(2):739-48 [10525095.001]
  • (PMID = 18581057.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA160777
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Quinazolines; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human
  •  go-up   go-down


12. Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS: Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer; 2005 Oct 1;104(7):1478-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-one patients (85%) had recurrent glioblastoma multiforme (GBM) and 16 (15%) had recurrent anaplastic glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Maximum Tolerated Dose. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16088964.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P20 CA096890; United States / NCI NIH HHS / CA / CA11898; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Nicolardi L, DeAngelis LM: Response to chemotherapy of a radiation-induced glioblastoma multiforme. J Neurooncol; 2006 May;78(1):55-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to chemotherapy of a radiation-induced glioblastoma multiforme.
  • BACKGROUND: Radiation-induced glioblastoma multiforme (GBM) is particularly resistant to treatment and therapeutic options are limited.
  • CONCLUSION: GBMs may be a late complication of radiation treatment for pediatric brain tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / therapeutic use. Glioblastoma / drug therapy. Neoplasms, Radiation-Induced / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Adult. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child, Preschool. Humans. Magnetic Resonance Imaging. Male. Radiotherapy, Adjuvant / adverse effects

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosci. 1989;15(4):176-80 [2485912.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1431-8 [10329596.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):172-8 [9442520.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):392-7 [1845944.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Br J Neurosurg. 1995;9(5):629-37 [8561935.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] Arch Environ Health. 1976 Jan-Feb;31(1):21-8 [1244805.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] J Neurosurg. 2005 May;102(4 Suppl):417-22 [15926395.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • (PMID = 16314941.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  •  go-up   go-down


14. Mäenpää HO: [The treatment of adult glioma is multiphasic]. Duodecim; 2010;126(14):1669-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The treatment of adult glioma is multiphasic].
  • Even patients with glioblastoma surviving over two years is not rare.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Early Diagnosis. Humans. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Patient Care Planning / organization & administration. Prognosis. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804085.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Finland
  • [Number-of-references] 21
  •  go-up   go-down


15. Noda SE, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A: Molecular advances of brain tumors in radiation oncology. Semin Radiat Oncol; 2009 Jul;19(3):171-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular advances of brain tumors in radiation oncology.
  • Glioblastoma, grade IV malignant glioma based on the World Health Organization classification, is the most common primary brain tumor in adults.
  • The dismal prognosis of glioblastoma patients is largely caused by the striking radioresistance of these tumors.
  • This review introduces these new targeted therapies in the context of current treatment options for patients with glioblastoma.
  • It is hoped that this combined approach will overcome the current limitations in the treatment of patients with glioblastoma and result in a better prognosis for these patients.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / therapy. Glioblastoma / genetics. Glioblastoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Humans. Prognosis. Signal Transduction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464632.001).
  • [ISSN] 1532-9461
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 87
  •  go-up   go-down


16. Barone G, Maurizi P, Tamburrini G, Riccardi R: Role of temozolomide in pediatric brain tumors. Childs Nerv Syst; 2006 Jul;22(7):652-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of temozolomide in pediatric brain tumors.
  • TMZ is able to cross the blood brain barrier and is stable at gastric acid pH so it has almost 100% oral bioavailability and is rapidly absorbed after it is taken orally.
  • TEMOZOLOMIDE IN CANCER PATIENTS: On the basis of the relatively safe toxicity and the findings achieved in adult malignant gliomas, phase I and II clinical trials were set up to evaluate the opportunity of using this novel drug in pediatric cancer, too.
  • CONCLUSIONS: In spite of the poor activity of TMZ against pediatric brain tumors, the use of the drug in combination with other compounds should be evaluated in phases I and II clinical trials.
  • Moreover, the evaluation of the methylation status of the O6-methylguanine DNA methyltransferase promoter in glioblastoma biopsy specimens could be assayed as a predictive factor of TMZ efficacy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Pediatrics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Children's Health.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):372-8 [12759623.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):425-9 [15266331.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):482-90 [8595163.001]
  • [Cites] Cancer Res. 1984 May;44(5):1772-5 [6713381.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] Br J Cancer. 1998 Sep;78(5):652-61 [9744506.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):118-31 [15313584.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] J Clin Oncol. 1999 May;17 (5):1516-25 [10334539.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):998-1007 [10741727.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Dec;52(6):459-64 [13680160.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(6):484-8 [9332462.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Int J Health Serv. 2002;32(4):669-707 [12456121.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):203-7 [12675312.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):4110-8 [11051264.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3037-43 [9738573.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84 [10837964.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]
  • [Cites] J Med Chem. 1984 Feb;27(2):196-201 [6694168.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):203-8 [15015788.001]
  • [Cites] Childs Nerv Syst. 2005 Jun;21(6):477-81 [15378329.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Invest New Drugs. 1998;16(1):77-9 [9740547.001]
  • (PMID = 16565851.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Number-of-references] 31
  •  go-up   go-down


17. Garbizu JM, Mateo-Sierra O, Pérez-Calvo JM, Iza B, Ruiz-Juretschke F: [Radiation-induced cranial tumors: clinical series and literature review]. Neurocirugia (Astur); 2008 Aug;19(4):332-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present 7 patients with RI brain tumors diagnosed and treated at our institution between 1990 and 2006.
  • Four patients developed meningiomas and three developed other tumors (one glioblastoma, one softtissue sarcoma and one hemangioblastoma).
  • [MeSH-minor] Adolescent. Adult. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurocirugia (Astur). 2008 Oct;19(5):470 [19043887.001]
  • (PMID = 18726043.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


18. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology; 2009 Oct 13;73(15):1200-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
  • BACKGROUND: Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM).
  • CONCLUSIONS: Contrast enhanced MRI does not adequately assess disease status during bevacizumab therapy for recurrent glioblastoma (GBM).

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2610-21 [17016557.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):55-7 [1512163.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9 [9223322.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):271-8 [18182667.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):339-47 [18389177.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):700-8 [18697955.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Nov;5(11):634-44 [18711427.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Neurology. 2009 Apr 7;72(14):1217-22 [19349600.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 [19167838.001]
  • [Cites] Neuro Oncol. 2009 Oct;11(5):550-5 [19332770.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [CommentIn] Neurology. 2010 Apr 13;74(15):1239-41 [20385899.001]
  • (PMID = 19822869.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5 R01 CA076423-09; United States / NCI NIH HHS / CA / UO1 CA-105663-01; United States / NCI NIH HHS / CA / 5 R01 CA121327-02; United States / NCI NIH HHS / CA / CA92629-06; United States / NCI NIH HHS / CA / 2 P30 CA008748-27; United States / NCI NIH HHS / CM / 1N01 CM-62206
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2839807
  •  go-up   go-down


19. Magrassi L, Bongetta D, Bianchini S, Berardesca M, Arienta C: Central and peripheral components of writing critically depend on a defined area of the dominant superior parietal gyrus. Brain Res; 2010 Jul 30;1346:145-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the clinical and neuropsychological features of a patient with combined agraphia for handwriting and typewriting bearing a small glioblastoma in the left parietal lobe.
  • [MeSH-minor] Adult. Aged, 80 and over. Astrocytoma / surgery. Brain Mapping. Brain Neoplasms / surgery. Craniotomy. Electroencephalography. Female. Frontal Lobe / physiology. Humans. Magnetic Resonance Imaging. Male. Psycholinguistics. Reading

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20580692.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Deighton RF, McGregor R, Kemp J, McCulloch J, Whittle IR: Glioma pathophysiology: insights emerging from proteomics. Brain Pathol; 2010 Jul;20(4):691-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas account for >50% of adult primary intracranial tumors, with malignant gliomas (anaplastic astrocytomas and glioblastoma multiforme) being the most common.
  • An assessment of protein-protein interactions between these proteins compiled using novel web-based technology, revealed a robust and cohesive network for glioblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology


21. Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR: Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg; 2005 Nov-Dec;41(6):292-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients.
  • Pediatric glioblastoma multiforme (GBM) tumors, which have been established as 'de novo' neoplasms, are known to differ from their adult counterparts in terms of biology, genetics and ultimately survival of patients.
  • In order to evaluate the utility of markers of tumor biology for refining prognostic assessment, we retrospectively analyzed 54 pediatric GBMs (age range 9 months to 15 years) occurring at different anatomical sites in the brain, operated at our institute between 1995 and 2001.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Retinoblastoma Protein / metabolism. Tumor Suppressor Protein p53 / metabolism


22. Delion M, Moraru C, Almayrac F, Von Langsdorff D, Paquis P, Menei P: [Glioblastoma incident studies from May 2006 to May 2007 in Angers and Nice, France]. Neurochirurgie; 2010 Dec;56(6):499-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glioblastoma incident studies from May 2006 to May 2007 in Angers and Nice, France].
  • This study was conducted 2 years after the audit on incident glioblastoma in France in 2004.
  • New events that may modify the care or survival of glioblastoma have occurred since 2004, justifying the present study.
  • [MeSH-major] Brain Neoplasms / therapy. Glioblastoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. France. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20870254.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


23. Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, Javerzat S, Hagedorn M, Carrabba G, Lucini V, Gaini SM, Bresolin N, Bello L, Bikfalvi A, Torrente Y: Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res; 2007 Apr 1;67(7):3054-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
  • New experimental approaches have shown tumor regression after the grafting of neural stem cells and human mesenchymal stem cells into experimental intracranial gliomas of adult rodents.
  • However, the cell source seems to be an important limitation for autologous transplantation in glioblastoma.
  • In the present study, we evaluated the tumor targeting and antitumor activity of human skin-derived stem cells (hSDSCs) in human brain tumor models.
  • Taken together, these data validate the use of hSDSCs for targeting human brain tumors.
  • [MeSH-major] Brain Neoplasms / blood supply. Brain Neoplasms / therapy. Glioblastoma / blood supply. Glioblastoma / therapy. Skin / cytology. Stem Cell Transplantation. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409412.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1
  •  go-up   go-down


24. Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rössler K, Budka H, Hainfellner JA: No prognostic impact of survivin expression in glioblastoma. Acta Neuropathol; 2005 May;109(5):534-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No prognostic impact of survivin expression in glioblastoma.
  • In the present study we investigated the immunohistochemical expression of survivin and its prognostic impact in a large glioblastoma series comprising 104 consecutive adult patients undergoing a first operation for glioblastoma.
  • Survivin was expressed in all glioblastoma samples, and was prominent in a fraction of nuclei of tumor cells and vascular cells.
  • In summary, in glioblastoma, survivin is expressed predominantly in proliferating tumor cell nuclei.
  • [MeSH-major] Apoptosis / physiology. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioblastoma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western / methods. Cell Nucleus / metabolism. DNA Topoisomerases, Type II / metabolism. Female. Fluorescent Antibody Technique / methods. Humans. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / metabolism. Male. Microscopy, Confocal. Middle Aged. Models, Biological. Prognosis. Retrospective Studies. Statistics as Topic

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843906.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


25. Huang BC, Geng DY, Zee CS, Ji YM, Cheng HX, Dai YM: A unique magnetic resonance imaging feature of glioblastoma multiforme: the 'pseudopalisade' sign. J Int Med Res; 2010 Mar-Apr;38(2):686-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique magnetic resonance imaging feature of glioblastoma multiforme: the 'pseudopalisade' sign.
  • This study was designed to investigate the unique magnetic resonance imaging (MRI) appearance of histopathologically-proven glioblastoma multiforme (GBM) with pseudopalisade necrosis and to assess its value for grading gliomas and providing a differential diagnosis.
  • All patients underwent preoperative brain MRI including post-contrast T(1)-weighted imaging.
  • The presence of the 'pseudopalisade' sign on post-contrast T(1)-weighted images was compared among the different types of brain mass.
  • The 'pseudopalisade' sign on post-contrast T(1)-weighted images was useful for grading gliomas and for differentiating GBM from other brain masses.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Lymphatic Metastasis. Lymphoma / pathology. Lymphoma / surgery. Male. Middle Aged. Necrosis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Int Med Res. 2011;39(1):336
  • (PMID = 20515584.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL: Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer; 2008 Sep 1;113(5):1032-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme.
  • BACKGROUND: Regions of hypoxia within glioblastoma multiforme (GBM) are common and may influence a tumor's aggressiveness, response to treatment, and the patient's overall survival.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [Cites] J Neurooncol. 1999;44(3):255-66 [10720205.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] J Neurosurg Sci. 2000 Dec;44(4):203-9; discussion 209-10 [11327289.001]
  • [Cites] Curr Opin Genet Dev. 2001 Jun;11(3):293-9 [11377966.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):29-35 [11395850.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1337-43 [11535709.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):57-66 [11849564.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):903-11 [12213585.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):537-52 [12687910.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):65-73 [8699228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9 [9223322.001]
  • [Cites] Croat Med J. 2005 Jun;46(3):417-22 [15861521.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):324-30 [15967109.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Neuropathology. 2005 Sep;25(3):201-6 [16193836.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74 [16286386.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):193-200 [16234986.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):162-70 [16721804.001]
  • [Cites] Brain Pathol. 2006 Oct;16(4):273-86 [17107596.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2441-8 [17438103.001]
  • [Cites] Cancer Treat Res. 2004;117:79-95 [15015553.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):971-80 [15313390.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2468-71 [8653677.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Stat Med. 1997 Nov 30;16(22):2529-42 [9403954.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):513-20 [9488306.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Oct;57(10):931-6 [9786243.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Expert Rev Mol Med. 2005 Apr 15;7(6):1-16 [15831177.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4621-31 [11030151.001]
  • (PMID = 18618497.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093247-06; United States / NCI NIH HHS / CA / T32 CA093247-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  • [Other-IDs] NLM/ NIHMS58348; NLM/ PMC2574798
  •  go-up   go-down


27. Vajtai I, Reinert MM: Malignant glioneuronal tumor of the adult cerebrum with neuropil-like islands involving "proliferating nodules": confirmatory report of an unusual variant. Acta Neuropathol; 2007 Jun;113(6):711-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant glioneuronal tumor of the adult cerebrum with neuropil-like islands involving "proliferating nodules": confirmatory report of an unusual variant.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neuropil / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17429663.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Synaptophysin; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


28. Lau CJ, Koty Z, Nalbantoglu J: Differential response of glioma cells to FOXO1-directed therapy. Cancer Res; 2009 Jul 1;69(13):5433-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common adult primary brain tumors, and the most malignant form, glioblastoma multiforme, is invariably fatal.
  • The phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is altered in most glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / pathology. Forkhead Transcription Factors / drug effects. Glioma / pathology


29. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A: Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res; 2009 Oct 1;69(19):7548-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is the most common and most malignant adult brain tumor.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Membrane Proteins / biosynthesis. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773446.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / epidermal growth factor receptor VIII; 125267-21-2 / myristoylated alanine-rich C kinase substrate; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.13 / Protein Kinase C-alpha
  •  go-up   go-down


30. Shapiro WR, Carpenter SP, Roberts K, Shan JS: (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin Biol Ther; 2006 May;6(5):539-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite improvements in neurosurgery, radiotherapy and chemotherapy, few patients diagnosed with anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM) (WHO grades 3 and 4, respectively) will live beyond 2 years.
  • Most malignant gliomas cannot be completely resected or irradiated due to their ability to infiltrate diffusely into normal brain tissue.
  • Brain tissue is protected from the systemic circulation via the blood-brain barrier (BBB), which impedes entry of water-soluble chemotherapeutic agents into the tumour at therapeutic concentrations. (131)I-chTNT-1/B mAb (Cotara) employs an innovative strategy to treat the invasive portion of the tumour and the core lesion. (131)I-chTNT-1/B mAb is a genetically engineered, radiolabelled, chimeric monoclonal antibody specific for a universal intracellular antigen (i.e., DNA/histone H1 complex) exposed in the necrotic core of malignant gliomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. DNA / immunology. DNA / metabolism. Female. Histones / immunology. Histones / metabolism. Humans. Male. Middle Aged. Radioimmunotherapy / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610983.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Histones; 0 / Iodine Radioisotopes; 9007-49-2 / DNA
  •  go-up   go-down


31. Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramuzza D, Ravagnani F, Fossati-Bellani F: Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol; 2005 Jan;7(1):41-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologies were glioblastoma multiforme in 10, anaplastic astrocytoma in nine, and anaplastic oligodendroglioma in two; sites of origin were supratentorial areas in 17, spine in two, and posterior fossa in two.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Thiotepa / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Blood Component Transfusion. Child. Child, Preschool. Combined Modality Therapy. Erythroid Precursor Cells. Female. Humans. Male. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S1-5 [8971398.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(1):72-4 [9137533.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):2073-7 [9216666.001]
  • [Cites] Ann Genet. 1997;40(2):78-91 [9259954.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):553-9 [9324343.001]
  • [Cites] Med Pediatr Oncol. 1998 Feb;30(2):75-80 [9403013.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):210-21 [9440745.001]
  • [Cites] Childs Nerv Syst. 1997 Nov-Dec;13(11-12):572-7 [9454971.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2486-93 [9667268.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):661-7 [9818693.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):483-90 [9835900.001]
  • [Cites] Med Pediatr Oncol. 1999 Aug;33(2):83-7 [10398181.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2117-23 [10570440.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] Med Pediatr Oncol. 2000 Feb;34(2):147-50 [10657880.001]
  • [Cites] Childs Nerv Syst. 2000 Jan;16(1):15-20 [10672424.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):815-9 [11937316.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3569-72 [12552957.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):736-41 [2491958.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):583-8 [2319317.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):227-33 [1534708.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):112-8 [8478137.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1458-65 [8336185.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):428-36 [8084310.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):91-5 [9071906.001]
  • (PMID = 15701281.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  • [Other-IDs] NLM/ PMC1871624
  •  go-up   go-down


32. Arslan M, Karadeniz AN, Aksu G, Güveli M, Fayda M, Doğan AK, Akyüz F: Postoperative hypofractionated radiotherapy in glioblastoma multiforme. J BUON; 2006 Jan-Mar;11(1):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative hypofractionated radiotherapy in glioblastoma multiforme.
  • PURPOSE: To evaluate the safety and efficacy of hypofractionated radiotherapy (HRT) in glioblastoma multiforme (GM) patients in terms of overall and progression-free survival.
  • PATIENTS AND METHODS: Adult patients with GM were prospectively treated with HRT after total, subtotal or partial tumor excision.
  • Acute toxicity was minimal and only one HRT patient had late toxicity (brain necrosis).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Pilot Projects. Postoperative Period. Prognosis. Prospective Studies. Radiotherapy Planning, Computer-Assisted. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318950.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


33. Grabenbauer GG, Gerber KD, Ganslandt O, Richter A, Klautke G, Birkmann J, Meyer M: Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.
  • PURPOSE: To report a prospective, randomized, Phase II trial of radiotherapy with and without topotecan for the treatment of glioblastoma.
  • PATIENTS AND METHODS: Inclusion criteria were histology of glioblastoma, age <60 years, and Eastern Cooperative Oncology Group status 0-2.
  • These data might support further investigations into topotecan for the treatment of glioblastoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Topotecan / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Quality of Life. Radiotherapy Dosage. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19695435.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


34. Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA: Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys; 2006 Mar 1;64(3):892-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma accounted for 70% of the cases, and anaplastic oligodendroglioma histology (pure or mixed) was seen in 15% of the cases.
  • The median progression-free survival time for anaplastic astrocytoma and glioblastoma histology was 5.6 and 2.5 months, respectively.
  • The overall survival time for anaplastic glioma and glioblastoma was 36 and 9 months, respectively.
  • Intensity-modulated radiotherapy delivered with a limited number of beams did not result in an increased dose to the normal brain.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / radiation effects. Disease Progression. Female. Glioblastoma / radiotherapy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Oligodendroglioma / radiotherapy. Radiotherapy Dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458777.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP: Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol; 2008 May;69(5):506-9; discussion 509
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy. Stereotaxic Techniques
  • [MeSH-minor] Adult. Aged. Cohort Studies. Humans. Middle Aged. Reoperation / adverse effects. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262245.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW: A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg; 2010 Aug;113(2):192-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
  • OBJECT: This single-institution Phase II study tests the efficacy of adjuvant radioimmunotherapy with (125)I-labeled anti-epidermal growth factor receptor 425 murine monoclonal antibody ((125)I-mAb 425) in patients with newly diagnosed glioblastoma multiforme (GBM).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Iodine Radioisotopes / administration & dosage. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Receptor, Epidermal Growth Factor / immunology. Young Adult


37. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol; 2006 Jun 1;24(16):2563-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
  • PURPOSE: The European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada trial on temozolomide (TMZ) and radiotherapy (RT) in glioblastoma (GBM) has demonstrated that the combination of TMZ and RT conferred a significant and meaningful survival advantage compared with RT alone.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Canada. Chemotherapy, Adjuvant. Europe. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735709.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


38. Boiardi A, Bartolomei M, Silvani A, Eoli M, Salmaggi A, Lamperti E, Milanesi I, Botturi A, Rocca P, Bodei L, Broggi G, Paganelli G: Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol; 2005 Apr;72(2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
  • Twenty-six recurrent Glioblastoma (rGBM) patients sequentially treated at the National Neurological Institute 'C Besta' were enrolled for a second surgery in order to remove recurrent tumor and to place an Ommaya reservoire to allow local delivery of chemotherapy and local pre-targeted radio-immunotherapy (RIT).
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Mitoxantrone / administration & dosage. Radioimmunotherapy / methods. Yttrium Radioisotopes / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Bone Marrow Diseases / chemically induced. Chemotherapy, Adjuvant / methods. Combined Modality Therapy. Disease-Free Survival. Drug Delivery Systems / methods. Humans. Infusions, Intralesional. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Pilot Projects

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurooncol. 1988;6(1):75-83 [3397768.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Neurooncol. 1997 May;32(3):203-8 [9049881.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1303-11 [9615807.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):207-12 [11870507.001]
  • [Cites] Invest New Drugs. 1985;3(2):85-93 [2410393.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):1-17 [3275753.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5952s-5956s [7493376.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Biother Radiopharm. 2001 Jun;16(3):227-35 [11471487.001]
  • [Cites] J Neurooncol. 1991 Feb;10(1):57-74 [2022973.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):672-84 [9485020.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):631-8 [10210222.001]
  • [Cites] Eur J Cancer. 1978 Aug;14(8):851-6 [357162.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):157-62 [8699238.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):601-9 [10853818.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Strahlenther Onkol. 1992 Jun;168(6):361-8 [1621215.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1021-9 [7539062.001]
  • [Cites] Orv Hetil. 2002 May 26;143(21):1201-4 [12073541.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):383-9 [9054951.001]
  • [Cites] J Neurooncol. 1992 Sep;14 (1):19-35 [1335043.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1289-94 [11106118.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1255-61 [3768871.001]
  • [Cites] J Neurosurg. 2003 Apr;98(4):935-6; author reply 936 [12691429.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(10):585-92 [7929529.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):39-47 [11763421.001]
  • [Cites] Cancer. 1994 Feb 1;73(3 Suppl):1076-82 [8306250.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):397-409 [11139371.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):151-7 [10222435.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):255-7 [11300334.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):501-5 [11870527.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 15925992.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Yttrium Radioisotopes; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


39. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, Carpenter SP, Shan JS: Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery; 2005 Jun;56(6):1243-52; discussion 1252-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Fifty-one patients, 37 with recurrent glioblastoma multiforme, 8 with newly diagnosed glioblastoma multiforme, and 6 with recurrent anaplastic astrocytomas, were treated.
  • Treatment-emergent, drug-related central nervous system adverse events included brain edema (16%), hemiparesis (14%), and headache (14%).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Drug Delivery Systems. Glioma / radiotherapy. Radioimmunotherapy / methods. Radiopharmaceuticals / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Brain / pathology. Brain / radionuclide imaging. Cognition Disorders / etiology. Dose-Response Relationship, Radiation. Feasibility Studies. Female. Follow-Up Studies. Humans. Karnofsky Performance Status / statistics & numerical data. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Stereotaxic Techniques. Time Factors. Tomography, Emission-Computed, Single-Photon / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918940.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radiopharmaceuticals
  •  go-up   go-down


40. Balkanov AS, Makarenko MF, Poliakov PIu, Kachkov IA: [Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2005 Jul-Sep;(3):14-16; discussion 16-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain].
  • The postoperative use of lomustin, a nitrosourea agent, was investigated for its impact on the efficiency of hyperfractionated radiation therapy performed in patients with glioblastoma and anaplastic astrocytoma of the brain.
  • A total of 35 patients (26 and 9 patients with glioblastoma and anaplastic astrocytoma, respectively) were followed up.
  • Lomustin in combination with hyperfractionated radiation therapy was found to have no effect on the survival of patients with glioblastoma and anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy. Lomustine / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Combined Modality Therapy. Cranial Irradiation. Dexamethasone / therapeutic use. Dose Fractionation. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485820.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


41. Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P: Clinical significance of molecular biomarkers in glioblastoma. Can J Neurol Sci; 2010 Sep;37(5):625-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of molecular biomarkers in glioblastoma.
  • AIM: To review the impact of molecular biomarkers on response to therapy and survival in patients with primary glioblastoma (GBM).
  • [MeSH-major] Biomarkers / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Glioblastoma / diagnosis. Glioblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / therapeutic use. DNA Methylation / drug effects. DNA Methylation / genetics. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Regression Analysis. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21059509.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


42. Bondiau PY, Fauchon F, Jadaud E, Paquis P: [Radiotherapy in adult glioblastomas]. Neurochirurgie; 2010 Dec;56(6):486-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy in adult glioblastomas].
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Humans. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20869090.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


43. Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM: Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol; 2010 Jan;65(2):391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
  • PURPOSE: In order to evaluate the activity of gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM), a prospective single-center phase II study was conducted.
  • CONCLUSIONS: Concomitant radiotherapy-gemcitabine is active and well tolerated in newly diagnosed glioblastoma multiforme.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Deoxycytidine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Female. Humans. Magnetic Resonance Imaging. Male. Methylation. Middle Aged. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847425.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 0 / Tumor Suppressor Proteins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


44. De Toni A, Zbinden M, Epstein JA, Ruiz i Altaba A, Prochiantz A, Caillé I: Regulation of survival in adult hippocampal and glioblastoma stem cell lineages by the homeodomain-only protein HOP. Neural Dev; 2008 May 28;3:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of survival in adult hippocampal and glioblastoma stem cell lineages by the homeodomain-only protein HOP.
  • CONCLUSION: These data suggest that HOP participates in the regulation of the adult mouse hippocampal stem cell niche by negatively affecting cell survival.
  • HOP function thus appears to be critical in the adult brain in a region of continued plasticity, and its deregulation may contribute to disease.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7691-704 [11567059.001]
  • [Cites] Neurosci Lett. 2000 Sep 8;291(1):17-20 [10962143.001]
  • [Cites] Prog Neurobiol. 2002 Jan;66(1):1-18 [11897403.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] J Neurosci. 2002 Jul 15;22(14):6106-13 [12122071.001]
  • [Cites] Cell. 2002 Sep 20;110(6):713-23 [12297045.001]
  • [Cites] Cell. 2002 Sep 20;110(6):725-35 [12297046.001]
  • [Cites] Eur J Neurosci. 2002 Nov;16(9):1681-9 [12431220.001]
  • [Cites] Development. 2003 Jan;130(2):391-9 [12466205.001]
  • [Cites] Genomics. 2003 Jan;81(1):15-25 [12573257.001]
  • [Cites] J Comp Neurol. 2003 Jun 9;460(4):563-72 [12717714.001]
  • [Cites] Oncology. 2003;64(4):450-8 [12759545.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] J Neurosci. 2003 Dec 3;23(35):11112-9 [14657169.001]
  • [Cites] Development. 2003 Dec;130(26):6635-42 [14627719.001]
  • [Cites] EMBO J. 2004 Apr 21;23(8):1834-44 [15057274.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5281-9 [15169892.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):258-61 [15213722.001]
  • [Cites] Development. 2004 Aug;131(15):3805-19 [15240551.001]
  • [Cites] Trends Neurosci. 2004 Aug;27(8):447-52 [15271491.001]
  • [Cites] J Comp Neurol. 2004 Oct 25;478(4):359-78 [15384070.001]
  • [Cites] Nat Neurosci. 2004 Nov;7(11):1233-41 [15494728.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):84-7 [9695814.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Neuron. 1999 Jun;23(2):247-56 [10399932.001]
  • [Cites] Neuron. 1999 Jun;23(2):257-71 [10399933.001]
  • [Cites] J Neurosci. 2004 Nov 10;24(45):10040-6 [15537872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17132-7 [15569937.001]
  • [Cites] Development. 2005 Jan;132(2):335-44 [15604099.001]
  • [Cites] Physiol Rev. 2005 Apr;85(2):523-69 [15788705.001]
  • [Cites] Dev Biol. 2005 Jul 15;283(2):522-34 [15967424.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] EMBO Rep. 2005 Sep;6(9):885-90 [16113652.001]
  • [Cites] J Biol Chem. 2005 Sep 16;280(37):32531-8 [15929941.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1907-15 [16262630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):780-5 [16407118.001]
  • [Cites] Nat Rev Neurosci. 2006 Mar;7(3):179-93 [16495940.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Neurosci. 2001 Sep 15;21(18):7153-60 [11549726.001]
  • [Cites] Trends Neurosci. 2000 Jul;23(7):291-7 [10856938.001]
  • [Cites] J Neurosci. 2002 Mar 15;22(6):2255-64 [11896165.001]
  • (PMID = 18507846.001).
  • [ISSN] 1749-8104
  • [Journal-full-title] Neural development
  • [ISO-abbreviation] Neural Dev
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL071546-05A1; United States / NHLBI NIH HHS / HL / R01 HL071546; United States / NHLBI NIH HHS / HL / R01 HL071546-05A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HOP protein, human; 0 / Homeodomain Proteins; 0 / Hop protein, mouse; 0 / RNA, Small Interfering; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2416439
  •  go-up   go-down


45. Chawla S, Zhang Y, Wang S, Chaudhary S, Chou C, O'Rourke DM, Vossough A, Melhem ER, Poptani H: Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist Tomogr; 2010 Nov-Dec;34(6):836-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases.
  • OBJECTIVE: To differentiate glioblastomas, primary cerebral lymphomas (PCLs), and brain metastases using multivoxel proton magnetic resonance (MR) spectroscopic imaging.
  • METHODS: A total of 56 patients with brain neoplasms underwent MR imaging and proton MR spectroscopic imaging.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Lymphoma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Contrast Media. Creatine / metabolism. Diagnosis, Differential. Female. Gadolinium DTPA. Glutamic Acid / metabolism. Glutamine / metabolism. Humans. Inositol / metabolism. Lipid Metabolism. Magnetic Resonance Spectroscopy / methods. Male. Middle Aged. ROC Curve. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084897.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0RH81L854J / Glutamine; 30KYC7MIAI / Aspartic Acid; 3KX376GY7L / Glutamic Acid; 4L6452S749 / Inositol; 84F6U3J2R6 / gadodiamide; 997-55-7 / N-acetylaspartate; K2I13DR72L / Gadolinium DTPA; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


46. Tugcu B, Postalci LS, Gunaldi O, Tanriverdi O, Akdemir H: Efficacy of clinical prognostic factors on survival in patients with glioblastoma. Turk Neurosurg; 2010 Apr;20(2):117-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of clinical prognostic factors on survival in patients with glioblastoma.
  • AIM: Glioblastoma is the most common and highest-grade infiltrative astrocytoma.
  • Several distinct clinical parameters and molecular alterations have recently been described in glioblastoma.
  • MATERIAL AND METHODS: We evaluated 50 cases who were operated on for intracranial glioblastoma between January 1998-March 2004 retrospectively.
  • [MeSH-major] Brain Neoplasms / mortality. Glioblastoma / mortality. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / statistics & numerical data. Reoperation / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Prognosis. Retrospective Studies. Sex Distribution. Survival Analysis. Young Adult


47. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL: Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol; 2008 Mar;87(1):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
  • Methylation of the promoter region of the O ( 6 ) -methylguanine-DNA methyltransferase (MGMT) gene is known to be predictive of response to temozolomide treatment in patients with glioblastoma.
  • About 22 samples from 10 patients who had undergone multiple resections of a glioblastoma were examined with promoter sequencing.
  • [MeSH-major] DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Glioblastoma / genetics. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Nov;52(6):609-18 [8229080.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):553-61 [16254189.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):46-55 [16616111.001]
  • [Cites] Histol Histopathol. 2007 Sep;22(9):1005-15 [17523078.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):179-83 [16404435.001]
  • [Cites] Mutat Res. 2004 Apr 14;548(1-2):75-84 [15063138.001]
  • [Cites] Neurosurgery. 2007 Jul;61(1):E168-9; discussion E169 [17621007.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6119-29 [2205376.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1337-45 [12807730.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5380-7 [12154400.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):581-7 [15455376.001]
  • [Cites] Pharmacol Ther. 1997;74(3):285-97 [9352585.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3052-60 [8221573.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):1-8 [14712205.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5483-95 [12154409.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):807-14 [10213216.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):275-83 [15332332.001]
  • [Cites] Carcinogenesis. 1986 May;7(5):745-9 [3698202.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):525-32 [9927209.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18004504.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  •  go-up   go-down


48. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T: Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol; 2007 Jan;17(1):5-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On analysis of their respective recurrent tumors, five of six patients whose primary low-grade tumors carried p14(ARF) methylation exhibited homozygous co-deletions of the p14(ARF), p15(INK4b) and p16(INK4a) genes, which were restricted to glioblastoma as the most malignant end point.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. CpG Islands / physiology. Neoplasm Recurrence, Local / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Tumor Suppressor Protein p14ARF / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Methylation. Middle Aged. Mutation / genetics. Promoter Regions, Genetic / physiology. Survival Analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493032.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


49. Heineman EF, Ward MH, McComb RD, Weisenburger DD, Zahm SH: Hair dyes and risk of glioma among Nebraska women. Cancer Causes Control; 2005 Sep;16(7):857-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The etiology of brain cancer is not well understood.
  • For women with the most aggressive form of glioma, glioblastoma multiforme, risk increased with duration of exposure to 4.9 (95% CI = 1.6-15.7, 10 cases) after 21 or more years of permanent hair coloring use.
  • [MeSH-major] Brain Neoplasms / etiology. Glioma / etiology. Hair Dyes / adverse effects
  • [MeSH-minor] Adult. Case-Control Studies. Female. Glioblastoma / etiology. Humans. Middle Aged. Nebraska / epidemiology. Risk Assessment. Risk Factors. Survival Analysis. Women's Health

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132796.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Hair Dyes
  •  go-up   go-down


50. Gömöri E, Halbauer JD, Kasza G, Varga D, Horvath Z, Komoly S: Glioblastoma multiforme with an unusual location and clinical course. Clin Neuropathol; 2009 May-Jun;28(3):165-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme with an unusual location and clinical course.
  • We present a unique case of a brain tumor patient with atypical location and progression.
  • Postmortally, formalin-fixed brain demonstrated that the main tumor mass was located in the fornix, infiltrating the ventricular system and disseminating over the cortex, cerebellum and spinal cord.
  • [MeSH-major] Brain Neoplasms / diagnosis. Diagnostic Errors. Glioblastoma / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Accidents, Traffic. Adult. Anxiety / etiology. Fatal Outcome. Humans. Male. Mood Disorders / etiology. Stress Disorders, Post-Traumatic

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537131.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Rieske P, Zakrzewska M, Biernat W, Bartkowiak J, Zimmermann A, Liberski PP: Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome. J Neurooncol; 2005 Jan;71(1):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome.
  • We observed three neoplasms with completely different histologies: malignant fibrous histiocytoma (MFH), atypical meningioma (AM), and glioblastoma (GB), developing in a patient with Li-Fraumeni syndrome.
  • [MeSH-major] Germ-Line Mutation. Glioblastoma / genetics. Histiocytoma, Benign Fibrous / genetics. Li-Fraumeni Syndrome / genetics. Meningioma / genetics. Neoplasms, Multiple Primary / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Brain Neoplasms / genetics. Brain Neoplasms / therapy. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 22 / genetics. DNA / analysis. Fatal Outcome. Genetic Testing. Humans. Loss of Heterozygosity. Male. Microsatellite Repeats. Skin Neoplasms / genetics. Skin Neoplasms / therapy


52. Pyrko P, Schönthal AH, Hofman FM, Chen TC, Lee AS: The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res; 2007 Oct 15;67(20):9809-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here that GRP78 is expressed at low levels in normal adult brain, but is significantly elevated in malignant glioma specimens and human malignant glioma cell lines, correlating with their rate of proliferation.
  • Knockdown of GRP78 in glioblastoma cell lines induces CHOP and activates caspase-7 in temozolomide-treated cells.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / metabolism. Glioblastoma / drug therapy. Glioblastoma / metabolism. Heat-Shock Proteins / antagonists & inhibitors. Heat-Shock Proteins / biosynthesis. Molecular Chaperones / antagonists & inhibitors. Molecular Chaperones / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942911.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA027607; United States / NCI NIH HHS / CA / CA111700
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DDIT3 protein, human; 0 / Heat-Shock Proteins; 0 / Molecular Chaperones; 0 / RNA, Small Interfering; 0 / molecular chaperone GRP78; 147336-12-7 / Transcription Factor CHOP; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 3.4.22.- / Caspase 7; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


53. Andersson U, Schwartzbaum J, Wiklund F, Sjöström S, Liu Y, Tsavachidis S, Ahlbom A, Auvinen A, Collatz-Laier H, Feychting M, Johansen C, Kiuru A, Lönn S, Schoemaker MJ, Swerdlow AJ, Henriksson R, Bondy M, Melin B: A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol; 2010 Aug;49(6):767-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioma is the most common type of adult brain tumor and glioblastoma, its most aggressive form, has a dismal prognosis.
  • We investigated the genetic variants of EGFR, ERBB2, VEGFR and their ligands, EGF and VEGF on glioma and glioblastoma risk.
  • In addition, we evaluated the association of genetic variants of a newly discovered family of genes known to interact with EGFR: LRIG2 and LRIG3 with glioma and glioblastoma risk.
  • Material from four case-control studies with 725 glioma patients (329 of who were glioblastoma patients) and their 1 610 controls was used.
  • Results. Fourteen of the SNPs were significantly associated with glioma risk at p< 0.05, and 17 of the SNPs were significantly associated with glioblastoma risk at p< 0.05.
  • In addition, we found that one EGFR haplotype was related to increased glioblastoma risk at p=0.009, Odds Ratio [OR] = 1.67 (95% confidence interval (CI): 1.14, 2.45).
  • One SNP, rs4947986 next to the intron/exon boundary of exon 7 in EGFR, was validated in an independent data set of 713 glioblastoma and 2 236 controls, [OR] = 1.42 (95% CI: 1.06,1.91).
  • Discussion. Previous studies show that regulation of the EGFR pathway plays a role in glioma progression but the present study is the first to find that certain genotypes of the EGFR gene may be related to glioblastoma risk.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Polymorphism, Single Nucleotide. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Denmark. England. Female. Finland. Genotype. Haplotypes. Humans. Linkage Disequilibrium. Male. Middle Aged. Risk Assessment. Risk Factors. Sweden


54. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol; 2009 Feb 1;27(4):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
  • PURPOSE: This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9 [16626884.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 May;61(6):1059-67 [17694310.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1442-53 [10598712.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):207-18 [10454198.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1454-9 [15817350.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • (PMID = 19075262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / 2 P50 CA097257
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride
  • [Other-IDs] NLM/ PMC2645859
  •  go-up   go-down


55. Vidiri A, Carapella CM, Pace A, Mirri A, Fabi A, Carosi M, Giannarelli D, Pompili A, Jandolo B, Occhipinti E, Di Giovanni S, Crecco M: Early post-operative MRI: correlation with progression-free survival and overall survival time in malignant gliomas. J Exp Clin Cancer Res; 2006 Jun;25(2):177-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-seven patients with Glioblastoma (42) and Anaplastic Astrocytoma (5) were studied with MR 24 hrs after surgery.
  • [MeSH-major] Brain Neoplasms / mortality. Glioma / mortality. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Humans. Middle Aged. Postoperative Period. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918127.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


56. Sheikh U, Price CJ, Gutowski NJ: Gliomatosis presenting as a relative pupil-sparing third nerve palsy in a hypertensive diabetic. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MRI scan of brain showed thickening of both third nerves.
  • Further investigations revealed a glioblastoma.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Glioblastoma / diagnosis. Oculomotor Nerve Diseases / diagnosis
  • [MeSH-minor] Adult. Diabetes Mellitus, Type 2 / complications. Humans. Hypertension / complications. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surv Ophthalmol. 2002 Mar-Apr;47(2):137-57 [11918895.001]
  • [Cites] Am J Ophthalmol. 1999 Jul;128(1):94-6 [10482100.001]
  • [Cites] Jpn J Ophthalmol. 2008 Jan-Feb;52(1):32-5 [18369697.001]
  • [Cites] Neurology. 2001 Mar 27;56(6):797-8 [11274322.001]
  • (PMID = 22802234.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029609
  •  go-up   go-down


57. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ: Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer; 2008 Jul 15;113(2):405-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ) is now the standard of care for patients with newly diagnosed glioblastoma.
  • METHODS: The pre-RT and post-RT brain scans from patients treated with RT/TMZ for a malignant glioma were reviewed.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18484594.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


58. Andersen PB, Blinkenberg M, Lassen U, Kosteljanetz M, Wagner A, Poulsen HS, Sørensen PS, Paulson OB: A prospective PET study of patients with glioblastoma multiforme. Acta Neurol Scand; 2006 Jun;113(6):412-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective PET study of patients with glioblastoma multiforme.
  • OBJECTIVE: To study the post-surgical metabolic and structural cerebral changes in patients with glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging. Glioblastoma / metabolism. Glioblastoma / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / drug effects. Brain / metabolism. Brain / physiopathology. Female. Fluorodeoxyglucose F18. Glucose / metabolism. Humans. Male. Middle Aged. Neurosurgical Procedures / methods. Predictive Value of Tests. Prognosis. Prospective Studies. Radiotherapy / methods. Sample Size. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16674608.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


59. Nataf V, Kerrou K, Balogova S, Pene F, Huchet V, Gutman F, Prignon A, Muresan IP, Giannesini C, Izrael V, Schlienger M, Talbot JN: [Fluoroethylthyrosine 18F PET in the detection of brain tumours]. Bull Cancer; 2010 May;97(5):495-506
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fluoroethylthyrosine 18F PET in the detection of brain tumours].
  • PET with fluoroethylthyrosine (FET), amino-acid analogue, has been performed in Germany since the beginning of the decade for molecular and metabolic imaging of brain tumours, since FDG, the glucose analogue which is the reference tracer for clinical PET, has this drawback to be taken-up intensely by cerebral cortex.
  • We report on our preliminary results on the comparison of PET/CT with FET and FDG in 10 evaluable patients presenting with a brain lesion either at diagnosis or after treatment.
  • CONCLUSION: FET is a radiopharmaceutical with clinical usefulness for the diagnosis, delineation and monitoring of brain tumours.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Glioblastoma / radionuclide imaging. Glioma / radionuclide imaging. Humans. Male. Middle Aged. Oligodendroglioma / radionuclide imaging. Positron-Emission Tomography / methods. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374979.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


60. Dutta D, Vanere P, Gupta T, Munshi A, Jalali R: Factors influencing activities of daily living using FIM-FAM scoring system before starting adjuvant treatment in patients with brain tumors: results from a prospective study. J Neurooncol; 2009 Aug;94(1):103-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing activities of daily living using FIM-FAM scoring system before starting adjuvant treatment in patients with brain tumors: results from a prospective study.
  • BACKGROUND: Patients with brain tumors have varied degree of functional and psychological impairments because of factors relating to the tumor or to the treatment they receive.
  • MATERIAL AND METHOD: From August 2007 to April 2008, 150 consecutive adult (>18 years) primary brain tumor patients (median age 40 years; male 88, female 62) registered in a general out-patient neuro-oncology clinic were accrued and detailed data were recorded.
  • Glioblastoma (GBM) (23.3%), anaplastic astrocytoma (AA) (18.7%), and diffuse fibrillary astrocytoma (18.7%) were the commonest histologic subtypes.
  • [MeSH-major] Activities of Daily Living / psychology. Brain Neoplasms / psychology. Disability Evaluation. Stress, Psychological / psychology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Analysis of Variance. Female. Humans. Male. Middle Aged. Prospective Studies. Psychometrics. Retrospective Studies. Severity of Illness Index. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(1):36-41 [10749018.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):111-4 [18004503.001]
  • [Cites] Disabil Rehabil. 2004 Feb 18;26(4):235-45 [15164957.001]
  • [Cites] Spinal Cord. 1997 Jan;35(1):22-5 [9025215.001]
  • [Cites] Arch Phys Med Rehabil. 1993 Jun;74(6):566-73 [8503745.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):480-4 [10201420.001]
  • [Cites] J Neurooncol. 1997 Sep;34(2):187-92 [9210067.001]
  • [Cites] J Neurooncol. 2008 Dec;90(3):321-8 [18704269.001]
  • [Cites] Paraplegia. 1993 Jul;31(7):457-61 [8371936.001]
  • [Cites] Am J Phys Med Rehabil. 1993 Apr;72(2):84-9 [8476548.001]
  • [Cites] Disabil Rehabil. 1995 Jan;17(1):10-4 [7858276.001]
  • [Cites] Scand J Caring Sci. 1990;4(3):99-106 [2120762.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Nov;82(11):1540-6 [11689973.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):646-50 [10653880.001]
  • [Cites] J Clin Oncol. 1984 Mar;2(3):187-93 [6699671.001]
  • [Cites] J Neurol. 2008 Jun;255(6):820-7 [18500499.001]
  • (PMID = 19255726.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Port RE, Bernstein LJ, Barboriak DP, Xu L, Roberts TP, van Bruggen N: Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. Magn Reson Med; 2010 Aug;64(2):408-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.
  • Median decreases of 33% were found for both v(pe)(*) and K(trans.av*) in glioblastoma patients (n = 16) 24 hours after the administration of bevacizumab (P < 0.001).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / metabolism. Diffusion Magnetic Resonance Imaging / methods. Gadolinium DTPA / pharmacokinetics. Glioblastoma / drug therapy. Glioblastoma / metabolism
  • [MeSH-minor] Adult. Algorithms. Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Computer Simulation. Contrast Media / pharmacokinetics. Female. Humans. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Kinetics. Male. Metabolic Clearance Rate. Middle Aged. Models, Neurological. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20665785.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Contrast Media; 2S9ZZM9Q9V / Bevacizumab; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


62. Luetjens G, Mirzayan MJ, Brandis A, Krauss JK: Exophytic giant cell glioblastoma of the medulla oblongata. J Neurosurg; 2009 Mar;110(3):589-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic giant cell glioblastoma of the medulla oblongata.
  • Giant cell glioblastoma is a rare variant within the spectrum of glioblastoma multiforme (GBM) tumors.
  • A giant cell glioblastoma may be associated with a better prognosis than the common type of GBM after combined treatment involving tumor resection and radiochemotherapy.
  • A giant cell glioblastoma may occur at various sites in the brain and spinal cord.
  • Histopathological examination of the tumor revealed the typical features of a giant cell glioblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Medulla Oblongata
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061354.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, German Glioma Network: Long-term survival with glioblastoma multiforme. Brain; 2007 Oct;130(Pt 10):2596-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival with glioblastoma multiforme.
  • The median survival of glioblastoma patients is approximately 12 months.
  • To identify specific parameters that might be associated with this phenomenon, we performed a detailed clinical and molecular analysis of 55 primary glioblastoma long-term survivors recruited at the six clinical centres of the German Glioma Network and one associated centre.
  • Comparison of these data with results from an independent series of 141 consecutive unselected glioblastoma patients registered in the German Glioma Network revealed significantly more frequent MGMT hypermethylation in the long-term survivor group.
  • Taken together, our findings underline the association of glioblastoma long-term survival with prognostically favourable clinical factors, in particular young age and good initial performance score, as well as MGMT promoter hypermethylation.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. DNA, Neoplasm / genetics. Female. Genes, erbB-1. Humans. Karnofsky Performance Status. Loss of Heterozygosity. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. Prognosis. Risk Factors. Survivors. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785346.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 105
  •  go-up   go-down


64. Riva M, Salmaggi A, Marchioni E, Silvani A, Tomei G, Lorusso L, Merli R, Imbesi F, Russo A, Lombardia Neurooncology Group: Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group. Neurol Sci; 2006 Nov;27(5):345-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group.
  • A prospective, multicentre data collection on 132 adult newly diagnosed, histologically proven glioblastomas from 9 Lombardy hospitals collected in the same database during a one-year period was recently published.
  • From this database we report epidemiological and clinical characteristics in epilepsy-symptomatic (31%) glioblastoma patients vs. the group with other presenting symptoms (69%).
  • [MeSH-major] Brain Neoplasms. Epilepsy / complications. Epilepsy / epidemiology. Glioblastoma / complications. Glioblastoma / epidemiology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Demography. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Quality of Life. Retrospective Studies

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122945.001).
  • [ISSN] 1590-1874
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


65. Rhee W, Ray S, Yokoo H, Hoane ME, Lee CC, Mikheev AM, Horner PJ, Rostomily RC: Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia; 2009 Apr 1;57(5):510-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
  • The capacity of adult human glial progenitor cells (AGPs), to proliferate and undergo multipotent differentiation, positions them as ideal candidate cells of origin for human gliomas.
  • To investigate this potential role we identified AGPs as mitotically active Olig2 cells in nonneoplastic adult human brain and gliomas.
  • Extrapolating from a mean Olig2/Mib-1 labeling index (LI) of 52% and total cell number of 100 billion, we estimated the overall prevalence of mitotic Olig2 AGPs in nonneoplastic human brain parenchyma at 10 million.
  • In the most malignant Grade IV glioma, or glioblastoma multiforme (GBM), the prevalence of Olig2/Mib-1 cells was significantly decreased (24.5%).
  • The novel framework provided by this quantitative and comparative analysis supports future studies to examine the histogenetic role of Olig2 AGPs in adult gliomas, their potential contribution to the tumor stroma and the molecular role of Olig2 in glioma pathogenesis.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18837053.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007144; United States / NINDS NIH HHS / NS / T32 NS007144-25; United States / NINDS NIH HHS / NS / T32 NS007144-28; United States / NINDS NIH HHS / NS / T32 NS 0007144
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / MIB-1 antibody; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human
  • [Other-IDs] NLM/ NIHMS77469; NLM/ PMC4415884
  •  go-up   go-down


66. Matschke J, Tsokos M: Sudden unexpected death due to undiagnosed glioblastoma: report of three cases and review of the literature. Int J Legal Med; 2005 Sep;119(5):280-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden unexpected death due to undiagnosed glioblastoma: report of three cases and review of the literature.
  • A search for cases of sudden unexpected death due to undiagnosed glioblastoma from a total of 14,482 cases from the archives of the Institute of Legal Medicine in Hamburg in the period of 1991-2003 revealed only one such case.
  • A comprehensive literature review on cases of sudden death due to primary cerebral neoplasms published so far revealed a total of 83 cases with only ten cases of glioblastoma (12%), whereas 55 of these cases were due to histological benign tumors (66%).
  • [MeSH-major] Brain Neoplasms / diagnosis. Death, Sudden / etiology. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Aged. Autopsy. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1991 Apr;10(2):179-85 [1654403.001]
  • [Cites] Nihon Hoigaku Zasshi. 1993 Aug;47(4):336-9 [8397309.001]
  • [Cites] Int J Legal Med. 2004 Feb;118(1):32-6 [14625778.001]
  • [Cites] Am J Forensic Med Pathol. 1984 Jun;5(2):175-9 [6328972.001]
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1024-30 [11473451.001]
  • [Cites] Int J Legal Med. 2004 Apr;118(2):98-100 [14634832.001]
  • [Cites] Schweiz Rundsch Med Prax. 1981 May 12;70(20):899-901 [6940113.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Arch Kriminol. 1999 Mar-Apr;203(3-4):108-16 [10378044.001]
  • [Cites] Am J Forensic Med Pathol. 1980 Mar;1(1):29-45 [6263083.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):44-50 [11825924.001]
  • [Cites] Cancer. 1965 Jan;18:117-27 [14260073.001]
  • (PMID = 15864615.001).
  • [ISSN] 0937-9827
  • [Journal-full-title] International journal of legal medicine
  • [ISO-abbreviation] Int. J. Legal Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 18
  •  go-up   go-down


67. Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB: Bevacizumab for recurrent ependymoma. Neurology; 2009 Nov 17;73(20):1677-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recurrent glioblastoma, encouraging responses with bevacizumab have been observed.
  • METHODS: In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens.

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):211-6 [15614581.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):159-67 [19019565.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • (PMID = 19917990.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA-105663-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2788805
  •  go-up   go-down


68. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY: Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol; 2007 Jul;9(3):354-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The regimen consisted of low-dose etoposide (35 mg/m2 [maximum, 100 mg/day] daily for 21 days), alternating every 21 days with cyclophosphamide (2 mg/kg [maximum, 100 mg/day] daily for 21 days), in combination with daily thalidomide and celecoxib, in adult patients with recurrent malignant gliomas.
  • Twenty-eight patients had glioblastoma multiforme (GBMs), and 20 had anaplastic gliomas (AGs).
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Celecoxib. Cyclophosphamide / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neovascularization, Pathologic / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage. Thalidomide / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:169-77 [14531575.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):863-70 [14573787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22 [14561896.001]
  • [Cites] Semin Oncol. 1997 Apr;24(2):203-18 [9129690.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1027-33 [9149261.001]
  • [Cites] Pathol Oncol Res. 1998;4(1):62-75 [9555124.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4574-7 [10493510.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40 [15565458.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):295-9 [15735920.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):186-97 [15865884.001]
  • [Cites] Curr Oncol Rep. 2004 Jan;6(1):49-52 [14664761.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2030-8 [15026340.001]
  • [Cites] Blood. 2004 May 1;103(9):3549-51 [14726401.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):2-11 [15179620.001]
  • [Cites] Biomed Pharmacother. 2004 Oct;58(8):447-50 [15464874.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2673-80 [1423198.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Glia. 1995 Nov;15(3):339-47 [8586468.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):149-55 [8699237.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1877-84 [8656256.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):187-92 [8996141.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):213-9 [11957147.001]
  • [Cites] FASEB J. 2002 May;16(7):681-90 [11978732.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2731-5 [12019144.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1566-72 [12684433.001]
  • [Cites] J Cell Biochem. 2005 Sep 1;96(1):16-24 [16052525.001]
  • [Cites] Mol Ther. 2005 Nov;12(5):778-88 [16150649.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81 [16282886.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):327-34 [16195797.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):53-9 [16327979.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):33-9 [16786120.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):133-40 [16786136.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):313-32 [16807780.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Am J Hematol. 2000 Jan;63(1):35-7 [10602166.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] Am J Kidney Dis. 2000 Mar;35(3):539-43 [10692284.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4152-60 [10945623.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1195-206 [11181686.001]
  • [Cites] J Exp Med. 2001 Mar 5;193(5):607-20 [11238591.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):41-5 [11349879.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1951-2 [11419443.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1041-7 [11533708.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • (PMID = 17452651.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; 4Z8R6ORS6L / Thalidomide; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  • [Other-IDs] NLM/ PMC1907419
  •  go-up   go-down


69. Hau P, Kunz-Schughart LA, Rümmele P, Arslan F, Dörfelt A, Koch H, Lohmeier A, Hirschmann B, Müller A, Bogdahn U, Bosserhoff AK: Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas. J Neurooncol; 2006 Mar;77(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tenascin-C is an extracellular matrix protein known to correlate with prognosis in patients with glioblastoma, probably by stimulation of invasion and neoangiogenesis.
  • [MeSH-major] Brain Neoplasms / metabolism. Extracellular Matrix Proteins / metabolism. Glioma / metabolism. Tenascin / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child. Disease Progression. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Gliosarcoma / genetics. Gliosarcoma / metabolism. Gliosarcoma / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / analysis. Time Factors. Transforming Growth Factor beta1. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):937-42 [15033492.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] Radiother Oncol. 2004 Sep;72(3):297-303 [15450728.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):235-40 [11118570.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:163-7 [14531574.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):430-46 [15136790.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):1107-10 [11496325.001]
  • [Cites] Oncogene. 2004 Mar 4;23(9):1656-67 [15001984.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Mar;54(2):236-44 [7876891.001]
  • [Cites] Cancer Treat Res. 2004;117:169-90 [15015561.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1029-40 [10515226.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):251-8 [10861501.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2660-8 [11980665.001]
  • [Cites] Microsc Res Tech. 2001 Feb 15;52(4):401-10 [11170299.001]
  • [Cites] Acta Neuropathol. 1989;78(2):189-93 [2750489.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3622-33 [15116096.001]
  • [Cites] Int J Cancer. 1991 Aug 19;49(1):129-39 [1874566.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):199-203 [8054266.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):177-85 [11716069.001]
  • [Cites] Acta Neuropathol. 2002 Jul;104(1):85-91 [12070669.001]
  • [Cites] Biol Chem. 2002 Sep;383(9):1407-13 [12437133.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • (PMID = 16292494.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / TGFB1 protein, human; 0 / Tenascin; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


70. Yao Y, Kubota T, Takeuchi H, Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology; 2005 Sep;25(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean CD31-MVD and CD105-MVD was 36.7 and 24.8 for low-grade astrocytoma (LGA), 48.0 and 42.7 for anaplastic astrocytoma, 55.3 and 51.9 for glioblastoma multiforme (GBM), respectively.
  • [MeSH-major] Antibodies, Monoclonal. Astrocytoma / blood supply. Biomarkers, Tumor / analysis. Brain Neoplasms / mortality. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD. Antigens, CD31 / biosynthesis. Antigens, CD31 / immunology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Receptors, Cell Surface. Survival Analysis. Survival Rate. Vascular Cell Adhesion Molecule-1 / biosynthesis. Vascular Cell Adhesion Molecule-1 / immunology. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193836.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Cell Adhesion Molecule-1; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


71. Korshunov A, Sycheva R, Gorelyshev S, Golanov A: Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol; 2005 Sep;18(9):1258-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocytic gliomas are the most common pediatric brain tumors; however, nonbrainstem glioblastomas are extremely rare compared with their adult counterparts.
  • [MeSH-major] Brain Neoplasms / genetics. Genetic Markers. Glioblastoma / genetics


72. Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F, Hidaka T, Sugiyama K, Kurisu K: Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer; 2007 Mar 1;109(5):949-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geminin: a good prognostic factor in high-grade astrocytic brain tumors.
  • For this study, the authors investigated geminin expression in high-grade astrocytic tumors, including anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), with a view to predicting clinical outcomes on this basis in patients with these malignant brain tumors.
  • The relation of geminin expression to clinical outcome in these malignant brain tumors was analyzed by using the Kaplan-Meier method and a Cox proportional hazards regression model.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cell Cycle Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Female. Geminin. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17262828.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin
  •  go-up   go-down


73. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD, New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol; 2008 Aug;10(4):617-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-two patients had glioblastoma multiforme (GBM), 2 had anaplastic astrocytoma, and 1 had an anaplastic oliogodendroglioma; 24 patients had received one prior chemo therapy regimen before being enrolled in the study.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Clin Pharmacol. 2000 Jun;49(6):562-73 [10848720.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Br J Clin Pharmacol. 2002 Apr;53(4):355-62 [11966665.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):986-1001 [12461520.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):679-89 [12586806.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2965-72 [12912943.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4406-11 [15240529.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]
  • [Cites] J Neurochem. 1994 Dec;63(6):2240-7 [7964744.001]
  • [Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-11 [8587429.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Feb;276(2):473-81 [8632312.001]
  • [Cites] Biochim Biophys Acta. 1996 May 28;1311(3):155-63 [8664342.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):784-90 [9504938.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Circulation. 1998 Nov 24;98(21):2262-8 [9826312.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 18477765.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062406; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA62406; United States / NCI NIH HHS / CA / UO1 CA-62475
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidines; V6D7VK2215 / atrasentan
  • [Other-IDs] NLM/ PMC2666236
  •  go-up   go-down


74. Liu HE, Hsiao PY, Lee CC, Lee JA, Chen HY: NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population. Cancer Epidemiol Biomarkers Prev; 2008 Mar;17(3):661-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population.
  • The association of NAT2 polymorphisms with adult brain tumors has been unclear.
  • To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age- and gender-matched control subjects (n = 27 in each group).
  • The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95% confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95% confidence interval, 1.68-22.79; P = 0.0039).
  • The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016).
  • In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Brain Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349284.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


75. Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M, Kuroiwa T, Tsuji M, Imahori Y, Kirihata M, Sakurai Y, Masunaga S, Nagata K, Maruhashi A, Ono K: Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg; 2005 Dec;103(6):1000-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirteen patients, 10 of whom harbored a glioblastoma multiforme (GBM), one a gliosarcoma, one an anaplastic astrocytoma, and one an anaplastic oligoastrocytoma, were treated using this modified BNCT between January 2002 and December 2003.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Magnetic Resonance Imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Astrocytoma / radiotherapy. Boron Compounds / therapeutic use. Brain Edema / diagnosis. Brain Edema / etiology. Female. Glioblastoma / radiotherapy. Gliosarcoma / radiotherapy. Humans. Male. Middle Aged. Neutrons. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381186.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boron Compounds
  •  go-up   go-down


76. Michaud DS, Gallo V, Schlehofer B, Tjønneland A, Olsen A, Overvad K, Dahm CC, Teucher B, Lukanova A, Boeing H, Schütze M, Trichopoulou A, Lagiou P, Kyrozis A, Sacerdote C, Krogh V, Masala G, Tumino R, Mattiello A, Bueno-de-Mesquita HB, Ros MM, Peeters PH, van Gils CH, Skeie G, Engeset D, Parr CL, Ardanaz E, Chirlaque MD, Dorronsoro M, Sánchez MJ, Argüelles M, Jakszyn P, Nilsson LM, Melin BS, Manjer J, Wirfält E, Khaw KT, Wareham N, Allen NE, Key TJ, Romieu I, Vineis P, Riboli E: Coffee and tea intake and risk of brain tumors in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. Am J Clin Nutr; 2010 Nov;92(5):1145-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coffee and tea intake and risk of brain tumors in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study.
  • BACKGROUND: In a recent US cohort study, total coffee and tea consumption was inversely associated with risk of glioma, and experimental studies showed that caffeine can slow the invasive growth of glioblastoma.
  • We used Cox proportional hazards models to examine the relation between coffee and tea and brain tumors.
  • RESULTS: We observed no associations between coffee, tea, or combined coffee and tea consumption and risk of either type of brain tumor when using quantiles based on country-specific distributions of intake.
  • [MeSH-major] Brain Neoplasms / prevention & control. Coffee. Glioma / prevention & control. Phytotherapy. Plant Preparations / therapeutic use. Tea
  • [MeSH-minor] Adult. Aged. Anticarcinogenic Agents / adverse effects. Anticarcinogenic Agents / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Male. Meningioma. Middle Aged. Proportional Hazards Models. Prospective Studies. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20844074.001).
  • [ISSN] 1938-3207
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / / MC/ U106179471; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / G0401527; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Coffee; 0 / Plant Preparations; 0 / Tea
  •  go-up   go-down


77. Kim SH, Lee KG, Kim TS: Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma. Acta Cytol; 2007 May-Jun;51(3):375-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma.
  • OBJECTIVE: To evaluate the squash smear features of subependymal giant cell astrocytoma (SEGA) in comparison with gemistocytic astrocytoma and giant cell glioblastoma.
  • STUDY DESIGN: We compared the squash smear features of 3 cases of SEGA, 9 cases of gemistocytic astrocytoma and 3 cases of giant cell glioblastoma with the morphometric findings.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Male


78. Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzén L, Blomquist E, Westlin JE, Bergenheim AT, Swedish Brain Tumour Study Group: Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol; 2008 Aug;88(2):183-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
  • BACKGROUND AND PURPOSE: To evaluate the efficacy and safety of boron neutron capture therapy (BNCT) for glioblastoma multiforme (GBM) using a novel protocol for the boronophenylalanine-fructose (BPA-F) infusion.
  • The average weighted absorbed dose to normal brain was 3.2-6.1 Gy (W).
  • [MeSH-major] Boron Compounds / administration & dosage. Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Phenylalanine / administration & dosage
  • [MeSH-minor] Adult. Aged. Boron / blood. Female. Fructose / administration & dosage. Fructose / pharmacokinetics. Humans. Male. Middle Aged. Quality of Life. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. BORON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiother Oncol. 2008 Aug;88(2):287-8; author reply 288 [18617284.001]
  • (PMID = 18336940.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Boron Compounds; 30237-26-4 / Fructose; 47E5O17Y3R / Phenylalanine; N9E3X5056Q / Boron
  •  go-up   go-down


79. Galanaud D, Nicoli F, Confort-Gouny S, Le Fur Y, Dormont D, Girard N, Ranjeva J, Cozzone P: [Brain magnetic resonance spectroscopy]. J Radiol; 2007 Mar;88(3 Pt 2):483-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain magnetic resonance spectroscopy].
  • MR spectroscopy (MRS) sequences allow noninvasive exploration of brain metabolism during a MRI examination.
  • The most significant of the clinical uses are imaging intracranial tumors (positive and differential diagnosis, extension, treatment follow-up), diffuse brain injury, encephalopathies (especially hepatic and HIV-related), and the diagnosis of metabolic disorders.
  • [MeSH-major] Adrenoleukodystrophy / diagnosis. Brain / metabolism. Brain Diseases / diagnosis. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Brain Diseases, Metabolic / diagnosis. Brain Injuries / diagnosis. Brain Neoplasms / diagnosis. Canavan Disease / diagnosis. Child. Diagnosis, Differential. Female. Follow-Up Studies. Glioblastoma / diagnosis. Hepatic Encephalopathy / diagnosis. Humans. Male. Middle Aged. Mitochondrial Diseases / diagnosis. Multiple Sclerosis / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457259.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 68
  •  go-up   go-down


80. Dhermain F, Ducreux D, Bidault F, Bruna A, Parker F, Roujeau T, Beaudre A, Armand JP, Haie-Meder C: [Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma]. Bull Cancer; 2005 Apr;92(4):333-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma].
  • Glioblastoma multiforme still remains, at present, the most frequent and deadly primary malignant glioma in adult.
  • If morbidity has decreased with "non whole-brain" volumes, RT is nearly always failing locally, as surgery.
  • [MeSH-major] Brain Neoplasms / diagnosis. Diagnostic Imaging / methods. Glioblastoma / diagnosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888390.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 52
  •  go-up   go-down


81. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS: Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem; 2005 Jul 22;280(29):26953-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential induction of glioblastoma migration and growth by two forms of pleiotrophin.
  • Glioblastoma is the most common malignant brain tumor of adults and one of the most lethal cancers.
  • The secreted growth factor pleiotrophin (PTN) promotes glioblastoma migration and proliferation, initiating its oncogenic activities through two cell surface receptors, the protein tyrosine phosphatase receptor zeta (PTPRZ1) and the anaplastic lymphoma kinase (ALK), respectively.
  • Here, we report on the presence and purification of two naturally occurring forms of PTN (18 and 15 kDa) that differentially promote glioblastoma migration and proliferation.
  • Using a panel of glioblastoma cell lines, including low passage patient-derived cultures, we demonstrate that PTN15 promotes glioblastoma proliferation in an ALK-dependent fashion, whereas immobilized PTN18 promotes haptotactic migration of glioblastoma cells in a PTPRZ1-dependent fashion.
  • To demonstrate clinical relevance, we show that PTN15, PTN18, and PTPRZ1 are significantly overexpressed in glioblastoma relative to normal brain at both mRNA and protein levels using microarray, Western blot, and tissue microarray analyses on human tumors.
  • These results indicate that the PTN18-PTPRZ1 and the PTN15-ALK signaling pathways represent potentially important therapeutic targets for glioblastoma invasion and growth.
  • [MeSH-major] Carrier Proteins / physiology. Cytokines / physiology. Glioblastoma / pathology
  • [MeSH-minor] Adult. Cell Movement. Cell Proliferation. Humans. Neoplasm Invasiveness / pathology. Neoplasm Proteins / analysis. Nerve Growth Factors / physiology. Protein Processing, Post-Translational. Protein Tyrosine Phosphatases / analysis. Protein Tyrosine Phosphatases / physiology. Protein-Tyrosine Kinases. RNA, Neoplasm / analysis. Receptor Protein-Tyrosine Kinases. Receptor-Like Protein Tyrosine Phosphatases, Class 5. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908427.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5T32CA09056; United States / NINDS NIH HHS / NS / NS050151; United States / NINDS NIH HHS / NS / NS43147
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytokines; 0 / Neoplasm Proteins; 0 / Nerve Growth Factors; 0 / RNA, Neoplasm; 134034-50-7 / pleiotrophin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.1.3.48 / PTPRZ1 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5
  •  go-up   go-down


82. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD: A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol; 2008 Apr;10(2):182-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-one patients were enrolled in the study: 16 with glioblastoma multiforme (GBM) and 5 with anaplastic astrocytoma.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Oncology (Williston Park). 1994 Jan;8(1):81-6; discussion 86, 94, 97-8 [8123451.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3862-72 [11078500.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Neuro Oncol. 2004 Apr;6(2):119-26 [15134626.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Anticancer Res. 1984 May-Jun;4(3):133-40 [6465851.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):3029-36 [8200000.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1151-61 [7850714.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):530-5 [7897511.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] J Neurooncol. 1995;24(1):109-22 [8523067.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):37-44 [8641924.001]
  • [Cites] J Immunother. 1997 May;20(3):214-43 [9181460.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):631-8 [10210222.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):687-92 [10524423.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):47-55 [16111571.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):115-22 [16382120.001]
  • [Cites] J Cell Biochem. 1985;28(3):183-95 [4066774.001]
  • [Cites] Cancer Res. 1987 Apr 1;47(7):1941-6 [3815382.001]
  • [Cites] Cancer Res. 1988 Feb 1;48(3):559-66 [2446747.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Br J Neurosurg. 1988;2(2):179-91 [3267302.001]
  • [Cites] J Natl Cancer Inst. 1990 Dec 19;82(24):1918-21 [2250312.001]
  • [Cites] J Neuroimmunol. 1992 Jan;36(1):41-55 [1370958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):55-7 [1512163.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):583-91 [1429079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947-58 [10705017.001]
  • (PMID = 18287339.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / 1P50 CA 108786-01; United States / NCI NIH HHS / CA / CA 11898; United States / NINDS NIH HHS / NS / NS 20023; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Iodine Radioisotopes; 0 / Tenascin
  • [Other-IDs] NLM/ PMC2613820
  •  go-up   go-down


83. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T, ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery; 2008 Mar;62(3):564-76; discussion 564-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.
  • OBJECTIVE: The influence of the degree of resection on survival in patients with glioblastoma multiforme is still under discussion.
  • METHODS: Two hundred forty-three patients with glioblastoma multiforme per protocol from the 5-aminolevulinic acid study were analyzed.
  • However, bias and imbalances were controllable in the cohorts available from the 5-aminolevulinic acid study so that the present data now provide Level 2b evidence (Oxford Centre for Evidence-based Medicine) that survival depends on complete resection of enhancing tumor in glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Glioblastoma / mortality. Glioblastoma / surgery. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Bias (Epidemiology). Disease-Free Survival. Female. Germany / epidemiology. Humans. Male. Middle Aged. Prevalence. Reproducibility of Results. Risk Assessment. Risk Factors. Sensitivity and Specificity. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2009 Jun;64(6):E1206; author reply E1206 [19487874.001]
  • (PMID = 18425006.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Oppel F; Brune A; Lanksch W; Woiciechowsky C; Brock M; Vesper J; Tonn JC; Goetz C; Gilsbach JM; Mayfrank L; Oertel MF; Seifert V; Franz K; Bink A; Schackert G; Pinzer T; Hassler W; Bani A; Meisel HJ; Kern BC; Mehdorn HM; Nabavi A; Brawanski A; Ullrich OW; Böker DK; Winking M; Weber F; Langenbach U; Westphal M; Kähler U; Arnold H; Knopp U; Grumme T; Stretz T; Stolke D; Wiedemayer H; Turowski B; Pietsch T; Wiestler OD; Reulen HJ; Stummer W
  •  go-up   go-down


84. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


85. Liau CT, Wei KC, Tseng CK, Jung SM: Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. Chang Gung Med J; 2005 Jan;28(1):16-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
  • Of these, 20 had glioblastoma multiforme and 22 had anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804144.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


86. Roberts C, Issa B, Stone A, Jackson A, Waterton JC, Parker GJ: Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging; 2006 Apr;23(4):554-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Abdominal Neoplasms / pathology. Astrocytoma / pathology. Brain Neoplasms / pathology. Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Glioblastoma / pathology
  • [MeSH-minor] Adult. Aged. Area Under Curve. Female. Humans. Image Processing, Computer-Assisted. Linear Models. Male. Middle Aged. Neovascularization, Pathologic / pathology. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16506143.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


87. Schrot RJ, Ma JH, Greco CM, Arias AD, Angelastro JM: Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol; 2007 Nov;85(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme.
  • The role of stem cells in the origin, growth patterns, and infiltration of glioblastoma multiforme is a subject of intense investigation.
  • One possibility is that glioblastoma may arise from transformed stem cells in the ventricular zone.
  • To explore this hypothesis, we examined the distribution of two stem cell markers, activating transcription factor 5 (ATF5) and CD133, in an autopsy brain specimen from an individual with glioblastoma multiforme.
  • A 41-year-old male with a right posterior temporal glioblastoma had undergone surgery, radiation, and chemotherapy.
  • The brain was harvested within several hours after death.
  • To our knowledge, this is the first in situ demonstration of stem cell markers in whole human brain.
  • The robust staining for ATF5 and CD133 in histologically normal ventricular zone suggests that an increase in periventricular stem cell activity occurred in this patient on the side of the tumor, either as a localized response to brain injury or as an integral component of oncogenesis and tumor recurrence.
  • [MeSH-major] Activating Transcription Factors / metabolism. Antigens, CD / metabolism. Brain / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Glycoproteins / metabolism. Peptides / metabolism
  • [MeSH-minor] AC133 Antigen. Adult. Biomarkers / metabolism. Cerebral Ventricles / metabolism. Fatal Outcome. Humans. Immunohistochemistry. Male. Tissue Distribution

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2008 Sep;89(2):247-8; author reply 249 [18568293.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Acta Neuropathol. 1979 Mar 15;45(3):177-85 [442983.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] J Comp Neurol. 2006 Jan 20;494(3):415-34 [16320258.001]
  • [Cites] Mol Cell Neurosci. 2005 Jul;29(3):372-80 [15950153.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4590-600 [12805299.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nature. 1966 Jun 25;210(5043):1378-9 [6007120.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):907-16 [16170340.001]
  • [Cites] J Neurosci. 2005 Apr 13;25(15):3889-99 [15829641.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Neurosci. 2005 Jan 5;25(1):10-8 [15634762.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] Experientia. 1976 Nov 15;32(11):1467-8 [992001.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1313-7 [9809557.001]
  • [Cites] Cell. 1999 Jan 8;96(1):25-34 [9989494.001]
  • (PMID = 17516028.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 Antigen; 0 / ATF5 protein, human; 0 / Activating Transcription Factors; 0 / Antigens, CD; 0 / Biomarkers; 0 / Glycoproteins; 0 / PROM1 protein, human; 0 / Peptides
  •  go-up   go-down


88. Zhang C, Yao Y, Wang Y, Chen Z, Wu J, Mao Y, Zhou L: Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor. Int J Neurosci; 2010 Dec;120(12):787-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor.
  • Brain stem gliomas are rare intracranial tumors, especially in adults.
  • Malignant or high-grade brain stem gliomas are usually associated with a very poor prognosis.
  • This case report documents an adolescent harboring brain stem glioblastoma who had complete radiological response to temozolomide after partial tumor resection and survived for more than 3 years.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / mortality. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / mortality
  • [MeSH-minor] Fatal Outcome. Humans. Male. Survival Rate / trends. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20946086.001).
  • [ISSN] 1563-5279
  • [Journal-full-title] The International journal of neuroscience
  • [ISO-abbreviation] Int. J. Neurosci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


89. Utsuki S, Oka H, Suzuki S, Shimizu S, Tanizaki Y, Kondo K, Tanaka S, Kawano N, Fujii K: Pathological and clinical features of cystic and noncystic glioblastomas. Brain Tumor Pathol; 2006 Apr;23(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to review the different histological and clinical characteristics of glioblastoma multiforme (GBM) with and without cysts (cystic and noncystic GBM, respectively).
  • Thirty-seven GBM were collected; these were tumors for which more than 80% of the volume was surgically resected, including a portion of the peripheral parenchyma of the brain.
  • Thus, the prognosis for cystic GBM was significantly better than that for noncystic GBM, possibly because cystic GBMs showed comparatively little infiltration of the peritumoral brain parenchyma.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood-Brain Barrier / pathology. Brain / pathology. Coloring Agents. Cysts / pathology. Female. Humans. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095116.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


90. Seker A, Ozek MM: Congenital glioblastoma multiforme. Case report and review of the literature. J Neurosurg; 2006 Dec;105(6 Suppl):473-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital glioblastoma multiforme. Case report and review of the literature.
  • The authors report the case of a "definite" congenital glioblastoma multiforme (GBM) diagnosed with the aid of ultrasonography and fetal magnetic resonance (MR) imaging in the 37th week of gestation.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / ultrasonography. Glioblastoma / surgery. Glioblastoma / ultrasonography
  • [MeSH-minor] Adult. Cerebral Angiography. Female. Fetal Diseases / ultrasonography. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Pregnancy. Ultrasonography, Prenatal


91. Ishikawa E, Tsuboi K, Yamamoto T, Muroi A, Takano S, Enomoto T, Matsumura A, Ohno T: Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci; 2007 Aug;98(8):1226-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients.
  • A pilot study was performed to investigate the safety and feasibility of autologous formalin-fixed tumor vaccines (AFTV) and the clinical responses to these vaccines by glioblastoma multiforme (GBM) patients.
  • [MeSH-major] Cancer Vaccines. Glioblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / therapy. Feasibility Studies. Female. Fixatives. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Pilot Projects. Predictive Value of Tests. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17517052.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Fixatives
  •  go-up   go-down


92. Iuchi T, Hatano K, Narita Y, Kodama T, Yamaki T, Osato K: Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1317-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580493.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol; 2008 Jan 10;26(2):271-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 45 patients, 27 patients had glioblastoma multiforme, and 18 patients had anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Biomarkers, Tumor / analysis. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Hypoxia. Male. Middle Aged. Neovascularization, Pathologic. Proportional Hazards Models. Radiography. Retrospective Studies. Survival Analysis. Treatment Outcome. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):727-35 [16418497.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):626-35 [16837971.001]
  • [Cites] Nat Clin Pract Neurol. 2006 May;2(5):232-3 [16932555.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5260-4 [17000656.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):629-38 [17367605.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):299-310 [17415526.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3835-44 [17440098.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Histochem Cytochem. 2000 Aug;48(8):1103-10 [10898803.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2742-6 [12782577.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6130-4 [14559790.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):164-7 [14712082.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 18182667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS054276; United States / NCI NIH HHS / CA / R01 CA116659; United States / NCI NIH HHS / CA / CA116659; United States / NINDS NIH HHS / NS / K02 NS047409; United States / NINDS NIH HHS / NS / NS047409; United States / NINDS NIH HHS / NS / R01 NS054276
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS508913; NLM/ PMC3930173
  •  go-up   go-down


94. Samaras V, Piperi C, Korkolopoulou P, Zisakis A, Levidou G, Themistocleous MS, Boviatsis EI, Sakas DE, Lea RW, Kalofoutis A, Patsouris E: Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol Cell Biochem; 2007 Oct;304(1-2):343-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma, (grade IV astrocytoma), is characterized by rapid growth and resistance to treatment.
  • [MeSH-major] Astrocytoma / blood. Brain Neoplasms / blood. Enzyme-Linked Immunosorbent Assay / methods. Interleukin-10 / blood. Interleukin-10 / secretion. Interleukin-6 / blood. Interleukin-6 / secretion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Glioblastoma / blood. Humans. Leukocytes / secretion. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Nov 1;52(21):6020-4 [1394227.001]
  • [Cites] J Neurochem. 1998 Nov;71(5):1837-45 [9798907.001]
  • [Cites] Neuroimmunomodulation. 1998 May-Aug;5(3-4):214-9 [9730688.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):317-22 [7856743.001]
  • [Cites] J Immunol Methods. 1988 Nov 25;115(1):31-7 [3057075.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):12-6 [10360813.001]
  • [Cites] J Clin Immunol. 1992 Jul;12(4):239-47 [1512298.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):518-22 [11506489.001]
  • [Cites] J Neurochem. 1994 Sep;63(3):980-7 [7519668.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4882-92 [10202033.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1160-6; discussion 1166-7 [8584157.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):930-3 [16326273.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):97-101 [11147905.001]
  • [Cites] J Exp Med. 1991 Oct 1;174(4):915-24 [1655948.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):121-9 [11123284.001]
  • [Cites] Ann N Y Acad Sci. 1993 Jun 23;685:713-39 [8363277.001]
  • [Cites] Neurosurgery. 1994 Apr;34(4):669-72; discussion 672-3 [8008165.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3308-16 [15064729.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):29-34 [11949824.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6683-8 [2208133.001]
  • [Cites] Acta Neuropathol. 2002 Feb;103(2):171-8 [11810184.001]
  • [Cites] J Immunol. 1992 Feb 15;148(4):1143-8 [1737931.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5A):3217-24 [9413151.001]
  • [Cites] J Immunol Methods. 1997 Dec 29;210(2):149-66 [9520298.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Pathol Oncol Res. 1999;5(1):56-60 [10079380.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):265-73 [1625016.001]
  • [Cites] J Exp Med. 1993 Feb 1;177(2):523-7 [8426121.001]
  • [Cites] J Cell Physiol. 1997 Dec;173(3):335-42 [9369946.001]
  • [Cites] Brain Res. 1994 Jun 27;649(1-2):122-8 [7953624.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2358-66 [1382099.001]
  • [Cites] J Immunol. 1994 Mar 15;152(6):2720-8 [8144879.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):113-22 [9892093.001]
  • [Cites] J Immunol. 1992 May 15;148(10):3133-9 [1578140.001]
  • [Cites] J Neuroimmunol. 1998 Dec 1;92(1-2):50-9 [9916879.001]
  • [Cites] Clin Chem Lab Med. 2002 Sep;40(9):903-10 [12435107.001]
  • [Cites] Surg Neurol. 1980 Mar;13(3):161-3 [7368063.001]
  • [Cites] J Biol Chem. 1995 May 12;270(19):11463-71 [7744784.001]
  • (PMID = 17551671.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


95. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol; 2010 Dec;120(6):707-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • WHO grading of human brain tumors extends beyond a strictly histological grading system by providing a basis predictive for the clinical behavior of the respective neoplasm.
  • For example, patients with glioblastoma WHO grade IV usually show a less favorable clinical course and receive more aggressive first-line treatment than patients with anaplastic astrocytoma WHO grade III.
  • We sequenced the isocitrate dehydrogenase 1 gene (IDH1) at codon 132 in 382 patients with anaplastic astrocytoma and glioblastoma from the NOA-04 trial and from a prospective translational cohort study of the German Glioma Network.
  • The sequence from more favorable to poorer outcome was (1) anaplastic astrocytoma with IDH1 mutation, (2) glioblastoma with IDH1 mutation, (3) anaplastic astrocytoma without IDH1 mutation and (4) glioblastoma without IDH1 mutation (p < 0.0001).
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Glioma / classification. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Mutation / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / pathology. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Young Adult


96. Weigle B, Ebner R, Temme A, Schwind S, Schmitz M, Kiessling A, Rieger MA, Schackert G, Schackert HK, Rieber EP: Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep; 2005 Jan;13(1):139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant glioma comprises the majority of primary human brain tumors with 16,800 new cases reported each year in the USA.
  • The identification of potential target structures highly overexpressed in brain tumors is a crucial prerequisite for the activation of the immune defense against malignant glioma cells.
  • By screening an expression database for genes highly expressed in glioblastoma multiforme (GBM), we identified the Pit-Oct-Unc (POU) cooperating transcription factor SOX11 that is known to be crucially involved in brain development.
  • Analysis of the expression pattern of SOX11 in different normal adult and fetal tissues by multiple tissue dot blot and by a highly sensitive quantitative PCR assay confirmed the selective overexpression of SOX11 in fetal brain tissue.
  • Examination of tissue specimens obtained from malignant gliomas and from normal brain by quantitative real-time PCR (Q-RT-PCR) revealed upregulation of SOX11 in almost all tumor samples (15/16) as compared to the pooled normal brain.
  • We conclude that, after downregulation of SOX11 in the adult brain, its expression is reactivated during tumorigenesis and that SOX11 therefore represents a promising novel molecular target for adjuvant therapy of malignant gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioma / metabolism. High Mobility Group Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583815.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / High Mobility Group Proteins; 0 / POU Domain Factors; 0 / SOX11 protein, human; 0 / SOXC Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


97. DeAngelis LM: Chemotherapy for brain tumors--a new beginning. N Engl J Med; 2005 Mar 10;352(10):1036-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for brain tumors--a new beginning.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioblastoma / drug therapy. Medulloblastoma / drug therapy. O(6)-Methylguanine-DNA Methyltransferase / genetics
  • [MeSH-minor] Adult. Cerebellar Neoplasms / drug therapy. Chemotherapy, Adjuvant. Child, Preschool. Gene Silencing. Humans. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2005 Jun 2;352(22):2350-3; author reply 2350-3 [15938011.001]
  • [CommentOn] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [CommentOn] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [CommentOn] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • (PMID = 15758016.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


98. De Vita S, De Matteis S, Laurenti L, Chiusolo P, Sorà F, Piccirillo N, Reddiconto G, Fiorini A, Leone G, Sica S: Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM. Ann Oncol; 2006 Apr;17(4):720-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263757.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


99. Wang S, Kim S, Chawla S, Wolf RL, Zhang WG, O'Rourke DM, Judy KD, Melhem ER, Poptani H: Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage; 2009 Feb 1;44(3):653-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging.
  • The purpose of this study is to determine whether diffusion tensor imaging (DTI) metrics including tensor shape measures such as linear and planar anisotropy coefficients (CL and CP) can help differentiate glioblastomas from solitary brain metastases.
  • Sixty-three patients with histopathologic diagnosis of glioblastomas (22 men, 16 women, mean age 58.4 years) and brain metastases (13 men, 12 women, mean age 56.3 years) were included in this study.
  • The results demonstrated that FA, CL and CP from glioblastomas were significantly higher than those of brain metastases from all segmented regions (p<0.05), and the differences from the enhancing regions were most significant (p<0.001).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2005 Jun;235(3):985-91 [15833979.001]
  • [Cites] Magn Reson Med. 2006 Feb;55(2):439-49 [16402380.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 [16551981.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):609-11 [16552003.001]
  • [Cites] Neuroradiology. 2006 May;48(5):346-50 [16614822.001]
  • [Cites] Eur J Radiol. 2006 Jun;58(3):394-403 [16527438.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1362-9 [16775298.001]
  • [Cites] Radiology. 2006 Sep;240(3):803-10 [16926329.001]
  • [Cites] J Magn Reson Imaging. 2006 Dec;24(6):1259-68 [17096394.001]
  • [Cites] J Magn Reson Imaging. 2007 Apr;25(4):703-8 [17345634.001]
  • [Cites] Radiographics. 2007 May-Jun;27(3):883-8 [17495298.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jun-Jul;28(6):1078-84 [17569962.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Magn Reson Imaging. 2007 Sep;26(3):756-67 [17729339.001]
  • [Cites] NMR Biomed. 2008 Mar;21(3):208-16 [17530617.001]
  • [Cites] NMR Biomed. 2008 Jul;21(6):581-8 [18050359.001]
  • [Cites] Neuroimage. 2008 Oct 15;43(1):29-35 [18672074.001]
  • [Cites] Magn Reson Med. 2000 Aug;44(2):283-91 [10918328.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Apr;127(4):217-25 [11315255.001]
  • [Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]
  • [Cites] Med Image Anal. 2002 Jun;6(2):93-108 [12044998.001]
  • [Cites] J Neurol. 2002 Oct;249(10):1357-69 [12382150.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):435-55 [12489094.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):937-41 [12748097.001]
  • [Cites] J Neurooncol. 2003 Jun;63(2):109-16 [12825815.001]
  • [Cites] Magn Reson Med. 2004 Jan;51(1):140-7 [14705054.001]
  • [Cites] Radiology. 2004 Jul;232(1):221-8 [15220505.001]
  • [Cites] J Magn Reson Imaging. 2004 Aug;20(2):187-92 [15269942.001]
  • [Cites] J Magn Reson Imaging. 2004 Oct;20(4):555-62 [15390227.001]
  • [Cites] Am J Epidemiol. 1982 Jan;115(1):92-106 [7055134.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Jan;15(1):155-9 [8141048.001]
  • [Cites] Radiographics. 1996 Nov;16(6):1413-38; quiz 1462-3 [8946545.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Apr;16(2):187-98 [9101328.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):81-9 [9266444.001]
  • [Cites] Hum Brain Mapp. 1999;7(4):254-66 [10408769.001]
  • [Cites] Surg Neurol. 2005 Jan;63(1):56-61; discussion 61 [15639528.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):336-41 [15739563.001]
  • [Cites] Br J Radiol. 2005 Jun;78(930):533-7 [15900059.001]
  • [Cites] J Magn Reson Imaging. 2005 Jun;21(6):701-8 [15906339.001]
  • (PMID = 18951985.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102756-04; United States / NCI NIH HHS / CA / R01 CA102756; United States / NCI NIH HHS / CA / R01 CA102756-04; United States / NCI NIH HHS / CA / R01-CA102756
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS90639; NLM/ PMC2655208
  •  go-up   go-down


100. Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T: High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncol; 2005 Dec;6(12):953-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 29 patients with anaplastic astrocytoma and 61 patients with glioblastoma who received high-dose conformal radiotherapy during 1990-2002 were compared with 34 patients with anaplastic astrocytoma and 60 patients with glioblastoma who received conventional 60 Gy radiotherapy during 1979-89.
  • 77 of the 90 patients receiving high-dose radiotherapy were given 80 Gy; the remaining 13 patients, all with glioblastoma, received 90 Gy.
  • FINDINGS: Patients who received high-dose radiotherapy had significantly longer overall survival compared with those who received conventional radiotherapy (adjusted hazard ratio 0.30 [95% CI 0.12-0.76], p=0.011 for anaplastic astrocytoma and 0.49 [0.28-0.87], p=0.014 for glioblastoma).
  • Median survival in patients with glioblastoma was 16.2 months (12.8-19.6) for the high-dose group and 12.4 months (10.0-14.8) for the conventional group.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Dec;6(12):915-6 [16321754.001]
  • (PMID = 16321763.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down






Advertisement